Background and objectives: The atherogenic index of plasma (AIP) is elevated in fatty liver disease, but its value in non-obese people with non-alcoholic fatty liver disease (NAFLD) is unclear. This study aimed to investigate the relationship between AIP and NAFLD as well as to determine whether AIP might be used as an indicator of NAFLD in non-obese individuals. Methods : The present study involved non-obese Chinese and Japanese participants. Univariate and multivariate logistic regression models were used to determine risk factors. The performance of risk factors was compared according to the area under the receiver operating characteristic curve. Results : In the unadjusted model, the odds ratio (OR) for every 1 standard deviation (SD) increase in AIP was 52.30. In adjusted models I and II, the OR for every 1 SD increase in AIP was 36.57 and 50.84, respectively. The area under the receiver operating characteristic curve for AIP was 0.803 and 0.802 in the development and validation groups, respectively. The best cutoff value of AIP for discrimination between NAFLD and non-NAFLD was 0.005 in the Chinese group and-0.220 in the Japanese group. Conclusions : AIP and NAFLD are positively correlated in Chinese and Japanese populations. Therefore, AIP can be used as a new screening indicator for non-obese people with NAFLD in different nations.
And it is widely accepted that its photoluminescence (PL) emission is originated from the radiative transition between conduction band (CB), contributed by the π antibonding orbitals (π*) or δ* related to the sp 2 CN bond and valence band (VB) predominated by the lone pair (LP) in the edge N 2p orbitals. [3] Based on that the PL emission of g-C 3 N 4 in the region of 430-450 nm and 450-500 nm are ascribed to δ*→LP and π*→LP transition, respectively, the PL emission band can be controlled by adjusting π-conjugated polymeric network structure, the size of sp 2 CN clusters, layer packing, and defect degree. [4] However, pristine g-C 3 N 4 had low quantum yield (QY) and narrow range of PL emission (430-550 nm) due to its stable electronic band structure, [5] showing only slight changes in bandgaps upon different condensation precursors and reaction parameters (2.58-2.87 eV). [6] Over a decade, various functionalization strategies (including structural manipulation, [7] atomic/molecular doping, [8] and heterojunction construction [9] ) devoted to the electronic band structure adjustment, mainly aiming for the improvement of g-C 3 N 4 -related catalysis by enhancing their solar light (450-650 nm) is synthesized through the one-step molecular doping during the thermal condensation process of g-C 3 N 4 conjugated framework, which opens up its application beyond the conventional catalysis scopes. By adjusting the doped content of heteromolecules, the modified g-C 3 N 4 with the optical properties controlled according to the demand of practical applications can be facilely and largely obtained. It overcomes the limitation of the narrow adjusting range of conventional g-C 3 N 4 on optical properties and makes it become more promising for applications in solid-state displays. The corresponding multiple-color g-C 3 N 4 -based LED devices and the white-light LEDs with high quality can be obtained as supported by experiments and theoretical calculations. Moreover, the effect of doped molecule on the π-conjugated system of g-C 3 N 4 is systematically studied here, and the tunable luminescence mechanism is proposed.
Polymeric g-C 3 N 4 with controllable photoluminescence emission wavelength in the whole visible light range
Full-Color PhotoluminescenceThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.